Waystar Holding Corp. (WAY) Stock Forecast
Data as of Jul 31, 2026Healthcare · Current price $21.24 (+1.19%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 5, 2026 | Brian Peterson | Raymond James | $35.00 | +64.8% |
| Feb 19, 2026 | Stan Berenshteyn | Wells Fargo | $36.00 | +69.5% |
| Feb 18, 2026 | Brian Tanquilut | Jefferies | $41.00 | +93.0% |
| Feb 18, 2026 | Gene Mannheimer | Loop Capital Markets | $33.00 | +55.4% |
| Feb 18, 2026 | Jailendra Singh | Truist Financial | $38.00 | +78.9% |
| Feb 18, 2026 | Adam Hotchkiss | Goldman Sachs | $38.00 | +78.9% |
| Dec 15, 2025 | Kevin Caliendo | UBS | $41.00 | +93.0% |
| Dec 8, 2025 | Glen Santangelo | Barclays | $42.00 | +97.7% |
| Oct 30, 2025 | Richard Close | Canaccord Genuity | $54.00 | +154.2% |
| Oct 30, 2025 | Steven Valiquette | Mizuho Securities | $50.00 | +135.4% |
| Oct 14, 2025 | Saket Kalia | Barclays | $50.00 | +135.4% |
| Sep 18, 2025 | Constantine Davides | JMP Securities | $48.00 | +126.0% |
| May 7, 2025 | Jailendra Singh | Truist Financial | $50.00 | +135.4% |
| Apr 14, 2025 | Saket Kalia | Barclays | $45.00 | +111.9% |
| Oct 8, 2024 | Elizabeth Anderson | Evercore ISI | $32.00 | +50.7% |
| Sep 6, 2024 | Sean Dodge | RBC Capital | $31.00 | +46.0% |
| Aug 21, 2024 | Adam Hotchkiss | Goldman Sachs | $34.00 | +60.1% |
| Jul 3, 2024 | Sean Dodge | RBC Capital | $27.00 | +27.1% |
| Jul 3, 2024 | Stephanie Davis | Barclays | $24.00 | +13.0% |
| Jul 2, 2024 | George Hill | Deutsche Bank | $27.00 | +27.1% |
Top Analysts Covering WAY
WAY vs Sector & Market
| Metric | WAY | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 20 | 8 | 19 |
| Target Upside | +57.0% | +16366.1% | +18.0% |
| P/E Ratio | 31.70 | 2.98 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $1.28B | $1.29B | $1.30B | 17 |
| 2027-12-31 | $1.39B | $1.42B | $1.52B | 18 |
| 2028-03-31 | $377M | $380M | $391M | 6 |
| 2028-06-30 | $389M | $392M | $403M | 6 |
| 2028-09-30 | $398M | $401M | $412M | 11 |
| 2028-12-31 | $409M | $412M | $423M | 6 |
| 2029-03-31 | $367M | $371M | $381M | 7 |
| 2029-06-30 | $377M | $381M | $391M | 10 |
| 2029-09-30 | $382M | $386M | $396M | 7 |
| 2029-12-31 | $385M | $389M | $399M | 9 |
| 2030-12-31 | $1.82B | $1.85B | $1.93B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $1.59 | $1.63 | $1.66 | 13 |
| 2027-12-31 | $1.76 | $1.85 | $2.01 | 13 |
| 2028-03-31 | $0.50 | $0.50 | $0.52 | 6 |
| 2028-06-30 | $0.52 | $0.52 | $0.54 | 6 |
| 2028-09-30 | $0.53 | $0.54 | $0.56 | 7 |
| 2028-12-31 | $0.56 | $0.57 | $0.59 | 9 |
| 2029-03-31 | $0.57 | $0.58 | $0.60 | 8 |
| 2029-06-30 | $0.58 | $0.59 | $0.61 | 8 |
| 2029-09-30 | $0.60 | $0.61 | $0.63 | 9 |
| 2029-12-31 | $0.62 | $0.63 | $0.65 | 11 |
| 2030-12-31 | $2.62 | $2.67 | $2.81 | 1 |
Frequently Asked Questions
What is the analyst consensus for WAY?
The consensus among 20 analysts covering Waystar Holding Corp. (WAY) is Buy with an average price target of $35.21.
What is the highest price target for WAY?
The highest price target for WAY is $54.00, set by Richard Close at Canaccord Genuity on 2025-10-30.
What is the lowest price target for WAY?
The lowest price target for WAY is $24.00, set by Stephanie Davis at Barclays on 2024-07-03.
How many analysts cover WAY?
20 analysts have issued ratings for Waystar Holding Corp. in the past 12 months.
Is WAY a buy or sell right now?
Based on 20 analyst ratings, WAY has a consensus rating of Buy (2.00/5) with a +57.0% upside to the consensus target of $35.21.
What are the earnings estimates for WAY?
Analysts estimate WAY will report EPS of $1.63 for the period ending 2026-12-31, with revenue estimated at $1.29B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.